Alamar Biosciences, Inc.
28.96USD
-0.9900 (-3.31%)
Revenue
| (USD) | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|
| FY | — | — | 118.6M | 165.7M |
| Q1 | — | 13.1M | 26.0M | — |
| Q2 | — | 16.2M | 29.4M | — |
| Q3 | — | — | 30.2M | — |
| Q4 | — | — | 32.9M | — |
Revenue
| (USD) | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|
| FY | — | — | -1.16 | -.542 |
| Q1 | — | -.680 | -1.74 | — |
| Q2 | — | -.620 | -.220 | — |
| Q3 | — | — | -.201 | — |
| Q4 | — | — | -.201 | — |
Fiscal period: Reported, Estimated. Reported figures: SEC filings (EDGAR). Estimates are sell-side consensus for periods that have not reported. Earnings per share are restated onto today's share basis, so a period before a stock split is comparable with the ones after it.